Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.

ABSTRACT:

Aims

Dual inhibition of sodium-glucose cotransporter (SGLT) 1 and 2 with canagliflozin may offer additional metabolic effects beyond selective SGLT2 inhibition; however, its comparative cardiovascular associations remain uncertain. This study compared the risks of major adverse cardiovascular events (MACE) and all-cause mortality between canagliflozin and selective SGLT2 inhibitors in routine clinical practice.

Methods and results

We conducted a retrospective cohort study using a multicenter electronic health record database including over 118 million patients. Adults with type 2 diabetes, no prior cardiovascular disease, and new use of an SGLT inhibitor between January 2016 and December 2023 were identified. After applying strict exclusion criteria and 1:1 propensity score

SUBMITTER: Kornelius E 

PROVIDER: S-EPMC12580561 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature